Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 26, 2004
Business Overview: Henry Schein is the largest distributor of healthcare products and services to office-based practitioners in North America and Europe. Operations are divided into two segments: Healthcare Distribution (dental, medical, and international) and Technology (software and value-added services).
Key Financial Metrics
| Metric | Three Months Ended June 26, 2004 |
Six Months Ended June 26, 2004 |
|---|---|---|
| Net Sales | $945.7 million | $1,832.3 million |
| Gross Profit | $251.7 million | $482.5 million |
| Gross Margin | 26.6% | 26.3% |
| Operating Income | $63.6 million | $109.9 million |
| Net Income | $38.7 million | $67.1 million |
| Diluted EPS | $0.86 | $1.49 |
| Cash from Operations | N/A | $60.7 million |
| Total Debt | N/A | $509.0 million |
| Working Capital | N/A | $597.5 million |
Note: Three-month cash flow data is not explicitly provided in the summary tables; six-month data is used for liquidity analysis.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 21.8% for the quarter and 21.0% for the six-month period compared to the prior year. Growth was driven by 12.4% internal growth and 7.9% from acquisitions (net of divestitures) in the quarter.
- Segment Performance:
- Healthcare Distribution: Sales increased 22.1% (quarter) and 21.2% (six months). International sales grew 30.2% (quarter) due to acquisitions and currency effects.
- Technology: Sales increased 9.7% (quarter) and 11.0% (six months), driven by electronic services.
- Profitability: Operating income rose 13.5% for the quarter and 11.9% for the six months. Gross margins declined slightly (26.6% vs. 28.4% in the prior quarter) primarily due to increased sales of lower-margin vaccines and injectable pharmaceuticals.
- Acquisitions: The company acquired the Demedis Group (Germany, Italy, Benelux) on June 18, 2004, for approximately $315.5 million. This significantly increased goodwill and intangible assets.
- Debt Levels: Total debt increased from $256.4 million (Dec 2003) to $509.0 million (June 2004) to fund acquisitions, including a $150 million bridge loan.
Guidance, Outlook, and Risks
- Management Commentary: Management expects continued growth from the introduction of Colgate and Pentron product lines and increased sales of vaccines. The company anticipates higher working capital requirements due to sales growth and seasonal inventory patterns.
- Capital Allocation: The company completed a $100 million stock repurchase program in Q2 2004 and authorized a new $100 million repurchase program on June 21, 2004. No shares have been repurchased under the new program as of the filing date.
- Regulatory & Legal:
- Divestiture: The company divested the M&W business (part of Demedis) to satisfy German regulatory requirements, resulting in no gain or loss.
- Pending Approval: Regulatory review is ongoing for the acquisition of the Austrodent business (Austria).
- Litigation: Approximately 40 product liability cases are pending, including a Texas class action regarding software (class certification denied) and a New Jersey class action regarding vaccine sales (motions pending).
- Risks: Key risks include exposure to interest rate fluctuations (due to variable rate swaps and bridge loans), integration challenges with the Demedis Group, and potential impacts from healthcare reform and cost containment trends.
Investor Verification Checklist
- Acquisition Integration: Verify the successful integration of the Demedis Group and the realization of projected synergies.
- Debt Servicing: Monitor the refinancing of the $150 million bridge loan (maturing Dec 2004) and the impact of variable interest rates on future expenses.
- Margin Trends: Track gross margin stability as the mix of lower-margin pharmaceutical products increases.
- Regulatory Outcomes: Confirm the status of the Austrodent acquisition approval and the final resolution of pending class action lawsuits.
- Working Capital: Assess the company's ability to manage increased working capital needs driven by inventory forward buys and receivables days sales outstanding (DSO) which increased to 48.4 days.